信达生物涨超4% 信必敏 完成首批发货 公司与美年健康集团达成战略合作

智通财经
20 Mar

信达生物(01801)涨超4%,截至发稿,涨4.08%,报43.4港元,成交额5.12亿港元。消息面上,信达生物今早宣布,信必敏(替妥尤单抗N01)已经完成首批发货,并陆续抵达全国药房。据悉,信必敏是信达生物第15款产品,是中国首个、全球第二款IGF-1R单抗药物,是中国唯一获批能够逆转甲状腺突眼的无创突破性疗法。此外,3月18日,信达生物与美年健康集团达成深度战略合作。双方将充分发挥各自优势,以...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10